Table 6.
Laboratory abnormalities in all-treated patients with baseline normal values a
| |
Telavancin |
Standard therapy |
|---|---|---|
| n/N | n/N | |
| Hematocrit |
|
|
| Male, ≤30% |
1/4 (25%) |
0/1 (0%) |
| Female, ≤28% |
0/4 (0%) |
0/3 (0%) |
| WBC ≤2800/μl |
0/14 (0%) |
0/15 (0%) |
| Platelet count ≤75,000/μl |
0/18 (0%) |
0/13 (0%) |
| AST (≥3 ULN) |
3/18 (17%) |
0/18 (0%) |
| ALT (≥3 ULN) |
1/19 (5%) |
1/17 (6%) |
| Alkaline phosphatase (≥1.5 ULN) |
2/17 (12%) |
1/22 (5%) |
| Potassium <3 meq/l |
2/24 (8%) |
0/19 (0%) |
| Potassium >5.5 meq/l |
1/24 (4%) |
3/19 (16%) |
| Creatinine increase
b
|
5/25 (20%) |
2/28 (7%) |
| Baseline creatinine <1.5 mg/dl |
4/18 (22%) |
0/20 (0%) |
| Baseline creatinine ≥1.5 mg/dl | 1/7 (14%) | 2/8 (25%) |
ALT, alanine aminotransferase; AST, aspartate aminotransferase, ULN, upper limit of normal; WBC, white blood count.
a Includes laboratory assessments after initiation of study drug up to and including the earlier of the follow-up visit or 28 days after the last dose of study medication.
b Serum creatinine ≥1.5 mg/dl and at least 50% greater than baseline; includes patients with normal and abnormal values at baseline.